Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orphan-drug pipelines create dense disclosures, and Travere Therapeutics鈥� filings are no exception. Pages of clinical trial data, sparsentan milestones, and liquidity notes often leave investors scanning for what matters. If you鈥檝e ever wondered where to find 鈥淭ravere Therapeutics insider trading Form 4 transactions鈥� or how the company accounts for FDA fast-track expenses in a 10-Q, this page eliminates the guesswork. The result: Travere Therapeutics SEC filings explained simply.
Stock Titan鈥檚 AI reads every document the moment it hits EDGAR, then serves plain-English explanations. From the latest 鈥淭ravere Therapeutics quarterly earnings report 10-Q filing鈥� to a sudden 鈥淭ravere Therapeutics 8-K material events explained,鈥� our algorithms highlight cash runway, trial timelines, and risk factors. AG真人官方-time alerts keep you updated on 鈥淭ravere Therapeutics Form 4 insider transactions real-time,鈥� so you don鈥檛 miss an executive stock sale filed after the bell.
Need deeper context? Our platform links each form to the business questions professionals actually ask:
- 鈥淭ravere Therapeutics annual report 10-K simplified鈥� 鈥� see R&D spend, orphan-drug market size, and revenue projections in one view.
- 鈥淭ravere Therapeutics proxy statement executive compensation鈥� 鈥� compare CEO incentives to pivotal trial milestones.
- 鈥淭ravere Therapeutics earnings report filing analysis鈥� 鈥� track quarter-over-quarter pipeline progress without reading footnotes.
- 鈥渦nderstanding Travere Therapeutics SEC documents with AI鈥� 鈥� follow guided annotations inside each filing.
- 鈥淭ravere Therapeutics executive stock transactions Form 4鈥� 鈥� monitor patterns ahead of regulatory announcements.
Whether you鈥檙e modeling probability-of-approval or simply verifying cash reserves, Stock Titan delivers complete coverage, expert context, and AI-powered summaries that turn complex disclosures into actionable insights.
Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering $3.538 million of Autocallable Contingent Coupon Equity-Linked Securities linked to Target Corporation (TGT) stock, due July 6, 2027. The notes are unsecured senior obligations issued off the Series N MTN program and sold under prospectus supplement 424(b)(2).
Key economic terms:
- Stated principal: $1,000 per note; issue price 100%.
- Quarterly contingent coupon: 3.125 % (12.50 % p.a.) paid only if TGT鈥檚 closing price on the relevant valuation date is 鈮� coupon barrier.
- Coupon & final barriers: $54.258 (55 % of the $98.65 initial underlying value).
- Autocall: On six scheduled dates from Dec 30 2025 to Mar 30 2027 the notes redeem at par plus coupon if TGT 鈮� initial value.
- Maturity payment (if not called): Par if TGT 鈮� final barrier; otherwise investors receive 10.13685 TGT shares (or cash equivalent), exposing them to full downside below the 55 % barrier and potentially total loss.
- Estimated value at pricing: $974.50 (2.55 % below issue price) reflecting structuring and hedging costs. Underwriting fee up to $18.50; net proceeds $981.50 per note.
- The securities will not be listed; liquidity is expected to be limited to CGMI鈥檚 discretionary secondary market.
Risk highlights (PS-6 to PS-9): investors may lose all principal if TGT falls >45 %; coupons are not guaranteed; early redemption can curtail income; exposure to Citi credit risk; product priced above estimated value; secondary market, if any, likely below issue price. U.S. federal tax treatment uncertain; withholding possible for non-U.S. holders.
Citi-specific impacts: The $3.5 million offering is immaterial to Citigroup鈥檚 capital base, but generates fee income and hedging flows. Because the product embeds short-put/long-bond economics, Citi hedges via equity derivatives, benefitting from bid/offer and funding spreads disclosed.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
What is the primary focus of Travere Therapeutics Inc?
Which therapeutic areas does the company specialize in?
What is FILSPARI and how does it fit into the company鈥檚 portfolio?
What role does sparsentan play in Travere Therapeutics' pipeline?
How does Travere Therapeutics generate value within the biopharmaceutical industry?
What differentiates Travere Therapeutics from other biopharmaceutical companies?
How does the company approach regulatory challenges?
What are some challenges faced by Travere Therapeutics?
